{
    "root": "29d70fde-3c9c-433b-96fa-76a7e8815a63",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Sodium Chloride",
    "value": "20200127",
    "ingredients": [
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26710"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        }
    ],
    "indications": {
        "text": "0.9 % sodium chloride injection , usp indicated source water electrolytes may also used diluent reconstitution powdered liquid ( 10 ml ) product packaged vial 20 mm closure .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "important instructions \u20220.9 % sodium chloride injection , usp intended intravenous using sterile equipment . \u2022do connect flexible plastic containers series order avoid air embolism due possible residual air contained primary container . \u2022set vent closed position vented intravenous set prevent air embolism . \u2022use dedicated line without connections avoid air embolism . \u2022do pressurize intravenous solutions contained flexible plastic containers increase flow rates order avoid air embolism due incomplete evacuation residual air container . \u2022prior infusion , visually inspect solution particulate matter discoloration . solution clear precipitates . administer unless solution clear , container undamaged . dosing information choice product , , volume , rate , duration dependent upon age , weight condition patient concomitant therapy , determined physician experienced intravenous fluid therapy . introduction additives additives may incompatible . evaluate additions plastic container compatibility stability resulting preparation . consult pharmacist , available . , informed judgment physician , deemed advisable introduce additives , aseptic technique . mix thoroughly additives introduced . addition , discoloration and/or appearance precipitates , insoluble complexes crystals , . store solutions containing additives . discard unused portion .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "0.9 % sodium chloride injection , usp mini-bag plus container available follows : code size ( ml ) ndc 2b0042 50 0338-0553-11 2b0043 100 0338-0553-18 exposure pharmaceutical products heat minimized . avoid excessive heat . recommended product stored room temperature ( 25\u00b0c/77\u00b0f ) .",
    "adverseReactions": "none known .",
    "indications_original": "0.9% Sodium Chloride Injection, USP is indicated as a source of water and electrolytes and may also be used as diluent for reconstitution of a powdered or liquid (up to 10 mL) drug product packaged in a vial with a 20 mm closure.",
    "contraindications_original": "Important Administration Instructions \n                  \n                  \n                     \n                        \u20220.9 % Sodium Chloride Injection, USP is intended for intravenous administration using sterile equipment. \n                     \n                        \u2022Do not connect flexible plastic containers in series in order to avoid air embolism due to possible residual air contained in the primary container. \n                     \n                        \u2022Set the vent to the closed position on a vented intravenous administration set to prevent air embolism. \n                     \n                        \u2022Use a dedicated line without any connections to avoid air embolism. \n                     \n                        \u2022Do not pressurize intravenous solutions contained in flexible plastic containers to increase flow rates in order to avoid air embolism due to incomplete evacuation of residual air in the container. \n                     \n                        \u2022Prior to infusion, visually inspect the solution for particulate matter and discoloration. The solution should be clear and there should be no precipitates. Do not administer unless solution is clear, and container is undamaged. \n                  \n                  \n                     Dosing Information\n                  \n                  The choice of product, dosage, volume, rate, and duration of administration is dependent upon the age, weight and clinical condition of the patient and concomitant therapy, and administration should be determined by a physician experienced in intravenous fluid therapy.\n                  \n                     Introduction of Additives \n                  \n                  Additives may be incompatible. \n                  Evaluate all additions to the plastic container for compatibility and stability of the resulting preparation. Consult with a pharmacist, if available. \n                  If, in the informed judgment of the physician, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced. After addition, if there is a discoloration and/or the appearance of precipitates, insoluble complexes or crystals, do not use. Do not store solutions containing additives. Discard any unused portion.",
    "warningsAndPrecautions_original": "0.9% Sodium Chloride Injection, USP in MINI-BAG Plus Container is available as follows: \n                  \n                     \n                     \n                     \n                     \n                        \n                           \n                              \n                                 Code\n                              \n                           \n                           \n                              \n                                 Size (mL)\n                              \n                           \n                           \n                              \n                                 NDC\n                              \n                           \n                        \n                        \n                           \n                              2B0042\n                           \n                           \n                              50\n                           \n                           \n                              0338-0553-11\n                           \n                        \n                        \n                           \n                              2B0043\n                           \n                           \n                              100\n                           \n                           \n                              0338-0553-18\n                           \n                        \n                     \n                  \n                  Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored at room temperature (25\u00b0C/77\u00b0F).",
    "adverseReactions_original": "None known.",
    "drug": [
        {
            "name": "Sodium Chloride",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26710"
        }
    ]
}